Literature DB >> 19660668

Functional neurosurgery for movement disorders: a historical perspective.

Alim Louis Benabid1, Stephan Chabardes, Napoleon Torres, Brigitte Piallat, Paul Krack, Valerie Fraix, Pierre Pollak.   

Abstract

Since the 1960s, deep brain stimulation and spinal cord stimulation at low frequency (30 Hz) have been used to treat intractable pain of various origins. For this purpose, specific hardware have been designed, including deep brain electrodes, extensions, and implantable programmable generators (IPGs). In the meantime, movement disorders, and particularly parkinsonian and essential tremors, were treated by electrolytic or mechanic lesions in various targets of the basal ganglia, particularly in the thalamus and in the internal pallidum. The advent in the 1960s of levodopa, as well as the side effects and complications of ablative surgery (e.g., thalamotomy and pallidotomy), has sent functional neurosurgery of movement disorders to oblivion. In 1987, the serendipitous discovery of the effect of high-frequency stimulation (HFS), mimicking lesions, allowed the revival of the surgery of movement disorders by stimulation of the thalamus, which treated tremors with limited morbidity, and adaptable and reversible results. The stability along time of these effects allowed extending it to new targets suggested by basic research in monkeys. The HFS of the subthalamic nucleus (STN) has profoundly challenged the practice of functional surgery as the effect on the triad of dopaminergic symptoms was very significant, allowing to decrease the drug dosage and therefore a decrease of their complications, the levodopa-induced dyskinesias. In the meantime, based on the results of previous basic research in various fields, HFS has been progressively extended to potentially treat epilepsy and, more recently, psychiatric disorders, such as obsessive-compulsive disorders, Gilles de la Tourette tics, and severe depression. Similarly, suggested by the observation of changes in PET scan, applications have been extended to cluster headaches by stimulation of the posterior hypothalamus and even more recently, to obesity and drug addiction. In the field of movement disorders, it has become clear that STN stimulation is not efficient on the nondopaminergic symptoms such as freezing of gait. Based on experimental data obtained in MPTP-treated parkinsonian monkeys, the pedunculopontine nucleus has been used as a new target, and as suggested by the animal research results, its use indeed improves walking and stability when stimulation is performed at low frequency (25 Hz). The concept of simultaneous stimulation of multiple targets eventually at low or high frequency, and that of several electrodes in one target, is being accepted to increase the efficiency. This leads to and is being facilitated by the development of new hardware (multiple-channel IPGs, specific electrodes, rechargeable batteries). Still additional efforts are needed at the level of the stimulation paradigm and in the waveform. The recent development of nanotechnologies allows the design of totally new systems expanding the field of deep brain stimulation. These new techniques will make it possible to not only inhibit or excite deep brain structures to alleviate abnormal symptoms but also open the field for the use of recording cortical activities to drive neuroprostheses through brain-computer interfaces. The new field of compensation of deficits will then become part of the field of functional neurosurgery.

Entities:  

Mesh:

Year:  2009        PMID: 19660668     DOI: 10.1016/S0079-6123(09)17525-8

Source DB:  PubMed          Journal:  Prog Brain Res        ISSN: 0079-6123            Impact factor:   2.453


  14 in total

Review 1.  Parkinson's disease therapeutics: new developments and challenges since the introduction of levodopa.

Authors:  Yoland Smith; Thomas Wichmann; Stewart A Factor; Mahlon R DeLong
Journal:  Neuropsychopharmacology       Date:  2011-09-28       Impact factor: 7.853

Review 2.  Selective GABA release as a mechanistic basis of high-frequency stimulation used for the treatment of neuropsychiatric diseases.

Authors:  Thomas J Feuerstein; Miriam Kammerer; Carl Hermann Lücking; Andreas Moser
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2011-05-02       Impact factor: 3.000

3.  Functional remodeling of subtype-specific markers surrounding implanted neuroprostheses.

Authors:  Joseph W Salatino; Bailey M Winter; Matthew H Drazin; Erin K Purcell
Journal:  J Neurophysiol       Date:  2017-03-29       Impact factor: 2.714

4.  A Personalized Approach to Parkinson's Disease Patients Based on Founder Mutation Analysis.

Authors:  Nir Giladi; Anat Mirelman; Avner Thaler; Avi Orr-Urtreger
Journal:  Front Neurol       Date:  2016-05-10       Impact factor: 4.003

5.  Re-engineering the subthalamus.

Authors:  Dennis A Turner
Journal:  World Neurosurg       Date:  2012-05-24       Impact factor: 2.104

Review 6.  Non-human primate models of PD to test novel therapies.

Authors:  Marc Morissette; Thérèse Di Paolo
Journal:  J Neural Transm (Vienna)       Date:  2017-04-08       Impact factor: 3.575

7.  Proliferation of external globus pallidus-subthalamic nucleus synapses following degeneration of midbrain dopamine neurons.

Authors:  Kai Y Fan; Jérôme Baufreton; D James Surmeier; C Savio Chan; Mark D Bevan
Journal:  J Neurosci       Date:  2012-10-03       Impact factor: 6.167

8.  Reaching to proprioceptively defined targets in Parkinson's disease: effects of deep brain stimulation therapy.

Authors:  D Lee; D Y Henriques; J Snider; D Song; H Poizner
Journal:  Neuroscience       Date:  2013-04-13       Impact factor: 3.590

9.  The Subthalamic Nucleus becomes a Generator of Bursts in the Dopamine-Depleted State. Its High Frequency Stimulation Dramatically Weakens Transmission to the Globus Pallidus.

Authors:  Rachida Ammari; Bernard Bioulac; Liliana Garcia; Constance Hammond
Journal:  Front Syst Neurosci       Date:  2011-06-13

10.  Moving forward: advances in the treatment of movement disorders with deep brain stimulation.

Authors:  Terry K Schiefer; Joseph Y Matsumoto; Kendall H Lee
Journal:  Front Integr Neurosci       Date:  2011-11-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.